4-Amino-2-alkyl-butyramides as small molecule CCR2 antagonists with favorable pharmacokinetic properties

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 18, 2006, Pages 4715-4722

  Butora, Gabor ^a   Morriello, Gregori J ^a   Kothandaraman, Shankaran ^a   Guiadeen, Deodialsingh ^a   Pasternak, Alexander ^a   Parsons, William H ^a   MacCoss, Malcolm ^a   Vicario, Pasquale P ^a   Cascieri, Margaret A ^a   Yang, Lihu ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antagonists; CCR2; Chemokines

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR2 ANTAGONIST; N [3,5 BIS(TRIFLUOROMETHYL)BENZYL] 2 CYCLOPROPYL 4 (3' METHYL) 1'H SPIRO[INDENE 1,4 PIPERIDIN] 1' YLBUTANAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG RECEPTOR BINDING; DRUG SCREENING; HIGH THROUGHPUT SCREENING; IC 50; MONOCYTE; NONHUMAN; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ALKYLATION; AMIDES; AMINATION; ANIMALS; CELLS, CULTURED; CRICETINAE; HUMANS; MOLECULAR STRUCTURE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CHEMOKINE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33746850573     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.07.011     Document Type: Article

References (31)

1. Bachmann M.F., Kopf M., and Marsland B.J. Nat. Rev. Immunol. 6 (2006) 159
2. Onuffer J.J., and Horuk R. Trends Pharmacol. Sci. 23 (2002) 459
3. Bendall L. Histol. Histopathol. 20 (2005) 907
4. Wells T.N., Power C.A., Shaw J.P., and Proudfoot A.E. Trends Pharmacol. Sci. 27 (2006) 41
5. Pease J.E., and Williams T.J. Br. J. Pharmacol. 147 (2006) S212
6. Laing K.J., and Secombes C.J. Dev. Comp. Immunol. 28 (2004) 443
7. Tarrant T.K., and Patel D.D. Pathophysiology 13 (2006) 1
8. Sozzani S., Introna M., Bernasconi S., Polentarutti N., Cinque P., Poli G., Sica A., and Mantovani A. J. Leukocyte Biol. 62 (1997) 30
9. Quinones M.P., Estrada C.A., Kalkonde Y., Ahuja S.K., Kuziel W.A., Mack M., and Ahuja S.S. J. Mol. Med. 83 (2005) 672
10. Mahad D.J., and Ransohoff R.M. Sem. Immunol. 15 (2003) 23
11. Charo I.F., and Taubman M.B. Circ. Res. 95 (2004) 858
12. Dawson J., Miltz W., Mir A.K., and Wiessner C. Expert Opin. Ther. Targets 7 (2003) 35
13. Feria M., and Diaz-Gonzalez F. Expert Opin. Ther. Pat. 16 (2006) 49
14. Baba M., Nishimura O., Kanzaki N., Okamoto M., Sawada H., Iizawa Y., Shiraishi M., Aramaki Y., Okonogi K., Ogawa Y., Meguro K., and Fujino M. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 5698
15. Shiraishi M., Aramaki Y., Seto M., Imoto H., Nishikawa Y., Kanzaki N., Okamoto M., Sawada H., Nishimura O., Baba M., and Fujino M. J. Med. Chem. 43 (2000) 2049
16. Forbes I.T., Cooper D.G., Dodds E.K., Hickey D.M., Ife R.J., Meeson M., Stockley M., Berkhout T.A., Gohil J., Groot P.H., and Moores K. Bioorg. Med. Chem. Lett. 10 (2000) 1803
17. Witherington J., Bordas V., Cooper D.G., Forbes I.T., Gribble A.D., Ife R.J., Berkhout T., Gohil J., and Groot P.H. Bioorg. Med. Chem. Lett. 11 (2001) 2177
18. Mirzadegan T., Diehl F., Ebi B., Bhakta S., Polsky I., McCarley D., Mulkins M., Weatherhead G.S., Lapierre J.M., Dankwardt J., Morgans Jr. D., Wilhelm R., and Jarnagin K. J. Biol. Chem. 275 (2000) 25562
19. Moree W.J., Kataoka K., Ramirez-Weinhouse M.M., Shiota T., Imai M., Sudo M., Tsutsumi T., Endo N., Muroga Y., Hada T., Tanaka H., Morita T., Greene J., Barnum D., Saunders J., Kato Y., Myers P.L., and Tarby C.M. Bioorg. Med. Chem. Lett. 14 (2004) 5413
20. Van Lommen G., Doyon J., Coesemans E., Boeckx S., Cools M., Buntinx M., Hermans B., and Van Wauwe J. Bioorg. Med. Chem. Lett. 15 (2005) 497
21. Kettle J.G., Faull A.W., Barker A.J., Davies D.H., and Stone M.A. Bioorg. Med. Chem. Lett. 14 (2004) 405
22. 2, pH 7.4. 125I-hMCP-1 was purchased from Perkin Elmer Life Sciences, Inc., with a specific activity of 2200 Ci/mmol. The assay was terminated by filtration of the reaction mixture through GF/B filter plates (presoaked in 0.1% polyethyleneimine) using a Packard Cell Harvester. The filter plates were washed with 25 mM HEPES, pH 7.5, containing 500 mM NaCl and dried in an incubator for @ 37 °C for 30 min. The plates were loaded with Microscint 0 (Packard) and counted in a Topcount NXT (Packard). The software program Prism (GraphPad) was used for all calculations. All data represent mean values for at least two separate experiments.
23. Yang L., Zhou C., Guo L., Morriello G., Butora G., Pasternak A., Parsons W.H., Mills S.G., MacCoss M., Vicario P.P., Zweerink H., Ayala M.J., Goyal S., Hanlon W.A., Cascieri M.A., and Springer M.S. Bioorg. Med. Chem. Lett. 16 (2006) 3735
24. Yang, L.; Butora, G.; Jiao, R. X.; Pasternak, A.; Zhou, C.; Parsons, W. H.; MacCoss, M.; Vicario, P. P.; Ayala, M. J.; Cascieri, M. A. Discovery of 3-Piperidinyl-1-cyclopentanecarboxamide as a Novel Scaffold for Highly Potent CCR2 Receptor Antagonists, 226th National Meeting of the American Chemical Society, New York, NY, September 9, 2003.
25. Pasternak, A.; Marino, D.; Vicario, P. P.; Ayala, M. J.; Cascieri, M. A.; Davie, P.; Parsons, W. H.; Mills, S. G.; MacCoss, M.; Yang, L. Novel Orally Bioavailable γ-Aminoamide CCR2 Antagonists, 226th National Meeting of the American Chemical Society, New York, NY, September 9, 2003.
26. Pasternak, A.; Marino, D.; Vicario, P. P.; Ayala, M. J.; Cascieri, M. A.; Parsons, W. H.; Mills, S. G.; MacCoss, M.; Yang, L. J. Med. Chem., in press.
27. Evans B.E., Leighton J.L., Rittle K.E., Gilbert K.F., Lundell G.F., Gould N.P., Hobbs D.W., DiPardo R.M., Veber D.F., and Pettibone D.J. J. Med. Chem. 35 (1992) 3919
28. Evans D.A., Bartroli J., and Shih T.L. J. Am. Chem. Soc. 103 (1981) 2127
29. Evans D.A., Rieger D.L., Jones T.K., and Kaldor S.W. J. Org. Chem. 55 (1990) 6260
30. Morrissette M.M., Stauffer K.J., Williams P.D., Lyle T.A., Vacca J.P., Krueger J.A., Lewis S.D., Lucas B.J., Wong B.K., White R.B., Miller-Stein C., Lyle E.A., Wallace A.A., Leonard Y.M., Welsh D.C., Lynch J.J., and McMasters D.R. Bioorg. Med. Chem. Lett. 14 (2004) 4161
31. 4) were incubated in cell culture medium containing Fluo-3, AM fluorescent dye (5 μg/mL, Molecular Probes), and probenicid (710 μg/mL, Sigma) for 1 h at 37 °C. Cells were washed with Hanks buffer containing HEPES (20 mM), BSA (0.1%), and probenicid, and then were resuspended in 90 μL of the same buffer. A ligand addition plate was prepared by adding 135 μL of chemokines at various concentrations for the titration. To test inhibition of calcium release by TAK-779, 2 μL of this antagonist at various concentrations was added to the cells upon resuspension and 20 nM hMCP-1 was used to activate CCR2B receptors. Both plates were placed into the Fluorescence Imaging Plate Reader (FLIPR, Coherent, Inc.). Chemokines were dispensed from addition plate into the cell plate and calcium release was measured by the Argon Laser at an excitation wavelength of 488 nm and an emission wavelength of 530 nm.